{"groups":[{"description":"Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.\n\nParticipants suitable for allogeneic hematopoietic stem cell transplant (HSCT) after treatment with at least 1 cycle of blinatumomab may have undergone allogeneic HSCT instead of receiving further cycles with blinatumomab.","id":"FG000","title":"Blinatumomab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"67"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"116"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"48"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"68"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"This study was open to adults with a diagnosis of minimal residual disease (MRD; ≥ 10-³ leukemic cells) -positive B-precursor acute lymphoblastic leukemia (ALL) who were in complete hematologic remission."}